Literature DB >> 12553011

The essential 26S proteasome subunit Rpn11 confers multidrug resistance to mammalian cells.

Vito Spataro1, Katia Simmen, Claudio A Realini.   

Abstract

BACKGROUND: Identification of multidrug resistance (MDR) factors is crucial for designing chemotherapeutic strategies. Aberrant expression and dysfunction of proteasome subunits have been involved in malignant transformation and in cell resistance to various cytotoxic drugs.
MATERIALS AND METHODS: We analyzed the expression levels of the proteasome subunit Rpn11 in a panel of cancer cell lines, and studied the effect of Rpn11 overexpression on the resistance of mammalian cells to cytotoxic drugs in clonogenic cytotoxicity assay.
RESULTS: Rpn11 levels are highly variable in cancer cells; mammalian cells stably overexpressing Rpn11 display moderate resistance to vinblastine, cisplatin and doxorubicin, and also exhibit a slower proliferation rate when compared to the control cells.
CONCLUSION: Rpn11-overexpression in mammalian cells affects cell proliferation and the response to cytotoxic drugs, both of which may promote tumor cell escape from chemotherapeutic agents, and may serve as a marker for MDR-cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12553011

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  10 in total

1.  Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance.

Authors:  Y Song; S Li; A Ray; D S Das; J Qi; M K Samur; Y-T Tai; N Munshi; R D Carrasco; D Chauhan; K C Anderson
Journal:  Oncogene       Date:  2017-06-05       Impact factor: 9.867

2.  Crystal structure of the proteasomal deubiquitylation module Rpn8-Rpn11.

Authors:  Ganesh Ramnath Pathare; István Nagy; Paweł Śledź; Daniel J Anderson; Han-Jie Zhou; Els Pardon; Jan Steyaert; Friedrich Förster; Andreas Bracher; Wolfgang Baumeister
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-10       Impact factor: 11.205

3.  Participation of the proteasomal lid subunit Rpn11 in mitochondrial morphology and function is mapped to a distinct C-terminal domain.

Authors:  Teresa Rinaldi; Elah Pick; Alessia Gambadoro; Stefania Zilli; Vered Maytal-Kivity; Laura Frontali; Michael H Glickman
Journal:  Biochem J       Date:  2004-07-01       Impact factor: 3.857

Review 4.  Deubiquitinases and the new therapeutic opportunities offered to cancer.

Authors:  Roland Pfoh; Ira Kay Lacdao; Vivian Saridakis
Journal:  Endocr Relat Cancer       Date:  2015-02       Impact factor: 5.678

Review 5.  Inhibition of 19S proteasome-associated deubiquitinases by metal-containing compounds.

Authors:  Ningning Liu; Hongbiao Huang; Q Ping Dou; Jinbao Liu
Journal:  Oncoscience       Date:  2015-05-31

6.  POH1 deubiquitylates and stabilizes E2F1 to promote tumour formation.

Authors:  Boshi Wang; Aihui Ma; Li Zhang; Wei-Lin Jin; Yu Qian; Guiqin Xu; Bijun Qiu; Zhaojuan Yang; Yun Liu; Qiang Xia; Yongzhong Liu
Journal:  Nat Commun       Date:  2015-10-29       Impact factor: 14.919

Review 7.  Metal-based proteasomal deubiquitinase inhibitors as potential anticancer agents.

Authors:  Xin Chen; Qianqian Yang; Lu Xiao; Daolin Tang; Q Ping Dou; Jinbao Liu
Journal:  Cancer Metastasis Rev       Date:  2017-12       Impact factor: 9.264

Review 8.  POH1/Rpn11/PSMD14: a journey from basic research in fission yeast to a prognostic marker and a druggable target in cancer cells.

Authors:  Vito Spataro; Antoine Buetti-Dinh
Journal:  Br J Cancer       Date:  2022-05-02       Impact factor: 9.075

Review 9.  Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment.

Authors:  Huanjie Yang; Xin Chen; Kai Li; Hassan Cheaito; Qianqian Yang; Guojun Wu; Jinbao Liu; Q Ping Dou
Journal:  Semin Cancer Biol       Date:  2019-12-26       Impact factor: 15.707

10.  Requirement for POH1 in differentiation and maintenance of regulatory T cells.

Authors:  Yun Liu; Li Zhang; Boshi Wang; Zhaojuan Yang; Guiqin Xu; Aihui Ma; Ming Tang; Tiantian Jing; Lin Wu; Xiaoli Xu; Yongzhong Liu
Journal:  Cell Death Differ       Date:  2018-07-23       Impact factor: 15.828

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.